Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Accurately assessing treatment response and predicting recurrence in patients with locally advanced gastric cancer undergoing neoadjuvant chemotherapy is challenging. This study explores the use of circulating tumor DNA (ctDNA) and its combination with tumor markers (TM) for this purpose.
Patients And Methods: We retrospectively analyzed 44 patients, collecting plasma samples at pretreatment (T0), after neoadjuvant chemotherapy (T1), and 3-10 days after surgery (T2), along with tissue samples. Tumor markers (TMs), including carcinoembryonic antigen (CEA) and carbohydrate antigen (CA)19-9, CA72-4, CA125, and CA242, were also measured.
Results: ctDNA was detected in 64.1% of patients at T0, gradually decreasing to 41.0% at T1 and further to 33.3% at T2. Among those with ctDNA-positive at T0, 64.3% of the responders achieved ctDNA clearance, whereas only 8.3% of the non-responders exhibited this outcome (P = 0.005). When being positive at either T0 or T1 was defined as positive, 66.7% of patients were ctDNA positive, and 51.3% were TM positive. Combining both markers increased the overall positive rate to 94.9%. In assessing treatment effectiveness, the agreement with pathological response is 83.8%, higher than using ctDNA alone (76.9%) or TM (80.0%). After surgery, patients with ctDNA positive or TM positive (ctDNA+/TM+) showed worse overall survival (OS, HR 14.667; P < 0.001) compared with those negative for both (ctDNA-/TM-). ctDNA+/TM+ was an independent prognostic factor in a multivariate Cox analysis (adjusted HR 9.771, P = 0.045).
Conclusions: ctDNA demonstrates promise as a predictive marker for NACT response and recurrence risk. TMs can be cross complemented with ctDNA to better evaluate patient outcomes and enable more patients to be accurately evaluated.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1245/s10434-025-17397-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer.
J Clin Oncol
September 2025
Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine, Baltimore, MD.
Purpose: To assess modified folinic acid/leucovorin, fluorouracil, irinotecan, oxaliplatin (FOLFIRINOX; mFFX) versus gemcitabine/nab-paclitaxel (GnP) in de novo metastatic pancreatic ductal adenocarcinoma (PDAC) and explore predictive biomarkers.
Patients And Methods: Patients were randomly assigned 1:1 to mFFX or GnP with exclusion of germline pathogenic variants in or . The primary end point was progression-free survival (PFS) between arms with 0.
Interferon-induced senescent CD8 T cells reduce anti-PD1 immunotherapy efficacy in early triple-negative breast cancer.
Sci Transl Med
September 2025
Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Precision Cancer Medicine Center, Fudan University Shanghai Cancer Center, Shanghai 200032, P. R. China.
Triple-negative breast cancers (TNBCs) lack predictive biomarkers to guide immunotherapy, especially during early-stage disease. To address this issue, we used single-cell RNA sequencing, bulk transcriptomics, and pathology assays on samples from 171 patients with early-stage TNBC receiving chemotherapy with or without immunotherapy. Our investigation identified an enriched subset of interferon (IFN)-induced CD8 T cells in early TNBC samples, which predict immunotherapy nonresponsiveness.
View Article and Find Full Text PDFBinding of autotransporter adhesin CbpF to human CEACAM1 and CEACAM5: A Velcro model for bacterium adhesion.
Proc Natl Acad Sci U S A
September 2025
Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.
In eukaryotic systems, three major types of cell junctions have been well characterized. While bacterial adhesion mechanisms also exhibit remarkable diversity, the molecular processes that regulate the dynamic modulation of binding strength between elongated bacterial cells and host cells remain poorly understood. () utilizes the surface adhesin CbpF to interact with the highly expressed host receptors CEACAM1 and CEACAM5 on cancer cells to facilitate tumor colonization.
View Article and Find Full Text PDFPembrolizumab treatment in SMARCA4-deficient nonsmall cell lung cancer: high tumor mutational burden and programmed death-ligand 1(+) expression on circulating tumor cells for real-time monitoring: a case report.
Anticancer Drugs
September 2025
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College.
Nonsmall cell lung cancer (NSCLC) with SMARCA4 deficiency represents a rare subset of lung tumors characterized by early metastasis, poor response to chemotherapy, and unfavorable prognosis. Established therapy strategies for SMARCA4-deficient NSCLC remain elusive. While immune checkpoint inhibitors have been proposed as a potential solution, their efficacy remains uncertain.
View Article and Find Full Text PDFEvaluating the impact of relative dose intensity on efficacy of trastuzumab deruxtecan for metastatic breast cancer in the real-world clinical setting.
Ann Acad Med Singap
August 2025
Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
Introduction: Trastuzumab deruxtecan (T-DXd) has revolutionised treatment for metastatic breast cancer (MBC). While effective, its high cost and toxicities, such as fatigue and nausea, pose challenges.
Method: Medical records from the Joint Breast Cancer Registry in Singapore were used to study MBC patients treated with T-DXd (February 2021-June 2024).